Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study

Author: Goldstein Barry J.   Weissman Peter N.   Wooddell Margaret J.   Waterhouse Brian R.   Cobitz Alexander R.  

Publisher: Informa Healthcare

ISSN: 1473-4877

Source: Current Medical Research and Opinion, Vol.22, Iss.9, 2006-09, pp. : 1715-1723

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content